Recent Quotes
My Watchlist
Indicators
Star 60
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

7.475 +0.065 (+0.88%)
Streaming Delayed Price Updated: 11:31 AM EST, Jan 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Xeris Biopharma Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗
One of the company's key drugs won't be challenged by a competing medication anytime soon. 
Via The Motley Fool
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 8, 2025 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Xeris Biopharma Holdings ↗
 
Via Benzinga
News headline image
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗
Xeris Biopharma (XERS) Q3 2025 Earnings Transcript 
Via The Motley Fool
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates ↗
Xeris Biopharma posts record Q3 2025 revenue of $74.4M, up 37% YoY, but misses earnings estimates. The company raises full-year guidance. 
Via Chartmill
News headline image
Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris (XERS) Q2 Revenue Jumps 49% ↗
Via The Motley Fool
News headline image
Traders are paying attention to the gapping stocks in Thursday's session. ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗
Xeris Biopharma (XERS) Q2 2025 results beat estimates with $71.5M revenue (+48.8% YoY) and narrower losses. Stock surged 12.2% pre-market as Recorlev sales soared 136%. Raised full-year guidance to... 
Via Chartmill
Topics Earnings
News headline image
Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
XERIS Biopharma (XERS) meets Minervini’s Trend Template with strong technicals and high growth momentum, including 47.9% quarterly revenue growth and a 93.95 Relative Strength score. 
Via Chartmill
News headline image
Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Details for Analyst & Investor Day
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A High-Growth Stock Meeting Minervini’s Trend Template ↗
XERIS BIOPHARMA (XERS) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a stock to watch for momentum investors. 
Via Chartmill
News headline image
Xeris Biopharma Reports Record First Quarter 2025 Financial Results
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
From Bright Peak Therapeutics, Inc.
Via GlobeNewswire
News headline image
Would Mark Minervini consider XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) a top stock pick? ↗
Why the high growth investor may take a look at XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS). A fundamental and technical analysis of (NASDAQ:XERS). 
Via Chartmill
News headline image
Xeris Announces Changes to Its Board of Directors
From Xeris Biopharma Holdings, Inc.
Via Business Wire
News headline image
Xeris Announces Approval of Supplemental New Drug Application (sNDA) of Gvoke VialDx™ (glucagon) for Use as a Diagnostic Aid
From Xeris Biopharma Holdings, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.